Skip to main content
SpringerLink
Log in

Topoisomerase II in multiple drug resistance

  • Published:
Cytotechnology Aims and scope Submit manuscript

Abstract

Topoisomerase II is a target of alkaloid, anthracycline and related antitumor agents. Two types of multiple drug resistance are associated with these enzymes. In classical (typical) multidrug resistance, inhibitors are actively effluxed from cells by P-glycoprotein. In atypical multidrug resistance, topoisomerase II is either reduced in cellular content or mutated to a form that does not interact with inhibitors. Because cytotoxicity of most antineoplastic topoisomerase II inhibitors is directly related to the number of active topoisomerase II molecules, a reduction in this number leads to resistance. In the topoisomerase II mechanism, through which the DNA linking number is altered, DNA double strands are cleaved, and the termini transiently bound covalently (5′) or noncovalently (3′) to the enzyme while a second double strand is passed through the break in the first. This transition state complex then decays to enzyme and DNA of altered linking number. Most cytotoxic topoisomerase II inhibitors stabilize these reaction intermediates as ternary complexes, which are converted to lethal lesions when cells attempt to utilize the damaged DNA as templates. Toxicity is related to topoisomerase II content as well as to drug concentration. Thus, multidrug resistance results from either 1) decreasing cellular content of the inhibitor by P-glycoprotein (typical) or 2) decreasing cellular content and/or activity of the target, topoisomerase II, as, for example, when its content or activity is modulated downward by decreased expression, deactivation, or by mutations to the TopII gene, producing an enzyme that reacts poorly with inhibitors (atypical). Mixed types,i.e., both typical and atypical, are known. Attempts to abrogate or prevent both typical and atypical multidrug resistance to topoisomerase II inhibitors have been described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

atMDR:

atypical multidrug resistance

kDa:

kilodaltons

MDR:

multidrug resistance

Pgp:

P-glycoprotein

TOPO II:

topoisomerase II

References

  • Ackerman P, Glover CVC and Osheroff N (1985) Phosphorylation of topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activityin vitro. Proc Natl Acad Sci USA 82: 3164–3168.

    Google Scholar 

  • Baguley BC, Finlay GJ and Ching LM (1992) Resistance mechanisms to topoisomerase poisons: the application of cell culture methods. Oncol Res 4: 267–274.

    Google Scholar 

  • Bauer WR (1978) Structure and reactions of closed duplex DNA. Annu Rev Biophys Bioeng 7: 287–313.

    Google Scholar 

  • Beck WT (1989) Unknotting the complexities of multidrug resistance: The involvement of DNA topoisomerases in drug action and resistance. Journal of the NCI 81: 1683–1685.

    Google Scholar 

  • Beck WT and Danks MK (1991) Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin Cancer Biol 2: 235–244.

    Google Scholar 

  • Boege F, Gieseler F, Biersack H and Meyer P (1992) The measurement of nuclear topoisomerase II inhibitionin vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies. Eur J Clin Chem Clin Biochem 30: 63–68.

    Google Scholar 

  • Boiocchi M, Tumiotto L, Giannini F, Viel A, Biscontin G, Sartor F and Toffoli G (1992) P-glycoprotein but not topoisomerase II and glutathione-S-transferase-pi accounts for enhanced intracellular drug resistance in LoVo MDR human cell lines. Tumori 78: 159–166.

    Google Scholar 

  • Bugg BY, Danks MK, Beck WT and Suttle DP (1991) Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci USA 88: 7654–7658.

    Google Scholar 

  • Chan VTW, Ng SW and Eder JP (1993) Molecular-cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese-hamster ovary cell line. J Biol Chem 268: 2160–2165.

    Google Scholar 

  • Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM and Liu LF (1984) Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259: 13560–13566.

    Google Scholar 

  • Chung TDY, Drake FH, Tan KB, Per SR, Crooke ST, and Mirabelli CK (1989) Characterization and immunological identification of cDNA clones encoding two human topoisomerase II isozymes. Proc Natl Acad Sci USA 86: 9431–9435.

    Google Scholar 

  • Cole SP, Chanda ER, Dicke FP, Gerlach JH and Mirski SE (1991) Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 51: 3345–3352.

    Google Scholar 

  • Colombo T, Zucchetti M and D'Incalci M (1993) Cyclosporin A induces drastic modifications in Doxorubicin (Dx) distribution in mice. Proc Am Assoc Cancer Res 34: 322.

    Google Scholar 

  • Cook PR and Brazell IA (1975) Supercoils in human DNA. J Cell Sci 19: 261–279.

    Google Scholar 

  • Danks MK, Schmidt CA, Cirtain MC, Suttle DP and Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861–8869.

    Google Scholar 

  • Danks MK, Yalowich JC and Beck WT (1987) Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47: 1297–1301.

    Google Scholar 

  • Darkin S and Ralph RK (1986) Potentiation of 4′-(9-acridinyl-amino)methane sulphon-m-anisidide action by verapamil. Cancer Lett 30: 25–33.

    Google Scholar 

  • Deffie AM, Batra JK and Goldenberg GJ (1989) Direct correlation between topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and resistant P388 leukemia cell lines. Cancer Res 49: 58–62.

    Google Scholar 

  • Deffie AM, Bosman DJ and Goldenberg GJ (1989) Evidence for a mutant allele of the gene for DNA topoisomerase II in Adriamycin-resistant P388 murine leukemia cells. Cancer Res 49: 6879–6882.

    Google Scholar 

  • Deffie AM, McPherson JP, Gupta RS, Hedley DW and Goldenberg GJ (1992) Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II. Biochem Cell Biol 70: 354–364.

    Google Scholar 

  • De Jong S, Zijlstra JG, De Vries EGE and Mulder NH (1990) Reduced topoisomerase II activity and drug-induced DNA cleavage activity in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304–309.

    Google Scholar 

  • De Jong S, Zijlstra JG, Mulder NH and De Vries EG (1991) Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother Pharmacol 28: 461–464.

    Google Scholar 

  • Dickstein B, Barnes K, Fojo T and Bates, SE (1993) Modulation of P-glycoprotein (Pgp)-mediated progesterone transport by protein kinase inhibition. Proc Am Assoc Cancer Res 34: 317.

    Google Scholar 

  • Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST and Mirabelli CK (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28: 8154–8160.

    Google Scholar 

  • Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattern MR, Johnson RK, Crooke ST and Mirabelli CK (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells: Evidence for two forms of the enzyme. J Biol Chem 262: 16739–16747.

    Google Scholar 

  • Eckardt JR, Burris HA, Rodriguez GA, Fields SM, Rothenberg ML, Moore TD, Smith SC, Ganapathi R, Weiss GR, Johnson RK, Kuhn JG and Von Hoff DD (1993) A phase I study of the topoisomerase I and II inhibitors topotecan and etoposide (E). Proc Am Soc Clin Oncol 12: 137.

    Google Scholar 

  • Efferth T, Mattern J and Volm M (1992) Immunohistochemical detection of P-glycoprotein, glutathione-S-transferase, and DNA topoisomerase II in human tumors. Oncology 49: 368–375.

    Google Scholar 

  • Eng W-K, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP and Johnson RK (1990) Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Molec Pharmacol 38: 471–480.

    Google Scholar 

  • Estey E, Adlakha RC, Hittelman WN and Zwelling LA (1987) Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity. Biochemistry 26: 4338–4344.

    Google Scholar 

  • Ferguson PJ, Fisher MH, Stephenson J, Li D-h, Zhou B-s and Cheng Y-c (1988) Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48: 5956–5964.

    Google Scholar 

  • Fine RL, Patel J and Chabner BA (1988) Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85: 582–586.

    Google Scholar 

  • Fritzer M, Szekeres T, Berczi A and Goldenberg H (1993) Cytotoxic effects of a transferrin-Adriamycin conjugate in multidrug resistant KB cells. Proc Am Assoc Cancer Res 34: 319.

    Google Scholar 

  • Fry AM and Hickson ID (1993) Phosphorylation modulates the enzymatic activity of human topoisomerase IIα protein. Proc Am Assoc Cancer Res 34: 421.

    Google Scholar 

  • Ganapathi R, Kamath N, Constantinou A, Grabowski D, Ford J and Anderson A (1991) Effect of the calmodulin inhibitor trifluoperazine on phosphorylation of P-glycoprotein and topoisomerase II: relationship to modulation of subcellular distribution, DNA damage and cytotoxicity of doxorubicin in multidrug resistant L1210 mouse leukemia cells. Biochem Pharmacol 41: 21–26.

    Google Scholar 

  • Gellert M, Menzel R, Mizuuchi K, O'Dea MH and Friedman DI (1982) Regulation of DNA supercoiling inE. coli. Cold Spring Harbor Symp Quant Biol 47: 763–767.

    Google Scholar 

  • Giaccone G, Gazdar AF, Beck H, Zunino F and Capranico G (1992) Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52: 1666–1674.

    Google Scholar 

  • Glisson BS and Alpeter MD (1992) Multidrug resistance in a small cell lung cancer line: rapid selection with etoposide and differential chemosensitization with Cyclosporin A. Anti Cancer Drugs 3: 359–366.

    Google Scholar 

  • Glisson BS, Gupta R, Smallwood-Kentro S and Ross WE (1986) Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res 46: 1934–1938.

    Google Scholar 

  • Harker WG, Slade DL, Drake FH and Parr RL (1991) Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30: 9953–9961.

    Google Scholar 

  • Harris AL and Hochauser D (1992) Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31: 205–213.

    Google Scholar 

  • Heck MMS and Earnshaw WC (1986) Topoisomerase II: a specific marker for cell proliferation. J Cell Biol 103: 2569–2581.

    Google Scholar 

  • Heck MMS, Hittelman WN and Earnshaw WC (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85: 1086–1090.

    Google Scholar 

  • Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD and Zwelling LA (1991) Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 51: 4729–4731.

    Google Scholar 

  • Hofmann GA, Mirabelli CK and Drake FH (1990) Quantitative adaptation of the bacteriophage P4 unknotting assay for use in the biochemical and pharmacological characterization of topoisomerase II. Anti-Cancer Drug Design 5: 273–282.

    Google Scholar 

  • Hsieh T-s and Brutlag D (1980) ATP-dependent DNA topoisomerase fromD. melanogaster reversibly catenates duplex DNA rings. Cell 21: 115–125.

    Google Scholar 

  • Isabella P, Capranico G, Binaschi M, Tinelli S and Zunino F (1989) Evidence of topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells. Molecular Pharmacology 37: 11–16.

    Google Scholar 

  • Isabella P, Capranico G and Zunino F (1991) The role of topoisomerase II in drug resistance. Life Sci 48: 2195–2205.

    Google Scholar 

  • Ishikawa H, Kawano MM, Okada K, Tanaka H, Tanabe O, Sakai A, Asaoku H, Iwato K, Nobuyoshi M and Kuramoto A (1993) Expressions of DNA topoisomerase I and topoisomerase II gene and the genes possibly related to drug resistance in human myeloma cells. Br J Haematol 83: 68–74.

    Google Scholar 

  • Johnson RK and Howard WS (1982) Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4′-(9-acridinylamino)methanesulphon-m-anisidide. Eur J Cancer Clin Oncol 18: 479–484.

    Google Scholar 

  • Kamath N, Grabowski D, Ford J, Kerrigan D, Pommier Y and Ganapathi R (1992) Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selectedin vivo for resistance to mitoxantrone. Biochem Pharmacol 44: 937–945.

    Google Scholar 

  • Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T and Okada K (1992) Factors contributing to Adriamycin sensitivity in human xenograft tumors: the relationship between expression of the Mdr1, GST-pi, and topoisomerase II genes and tumor sensitivity to Adriamycin. Anticancer Res 12: 241–245.

    Google Scholar 

  • Kobayashi H, Dorai T, Holland JF, and Ohnuma T (1993) Characteristics of the cleavage reaction of human multidrug resistance (MDR) mRNA by hammerhead ribozymes. Proc Am Assoc Cancer Res 34: 325.

    Google Scholar 

  • Kohn KW, Ewig RAG, Erickson LC and Zwelling LA (1981) Measurements of strand breaks and cross-links by alkaline elution. In: EC Friedberg and PC Hanawalt (eds) DNA Repair: a Laboratory Manual of Research Techniques (pp. 397–401). New York: Marcell Dekker.

    Google Scholar 

  • Lee MS, Wang JC and Beran M (1992) Two independent amsacrine-resistant myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol 223: 837–843.

    Google Scholar 

  • Lefevre D, Riou JF, Ahomadegbe JC, Zhou DY, Benard J and Riou G (1991) Study of molecular markers of resistance tom-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase. Biochem Pharmacol 41: 1967–1979.

    Google Scholar 

  • Ling V and Thompson LH (1974) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83: 103–116.

    Google Scholar 

  • Ling V (1992) P-glycoprotein and resistance to anticancer drugs. Cancer 69: 2603–2609.

    Google Scholar 

  • Liu LF (1983) DNA topoisomerases — enzymes that catalyse the breaking and rejoining of DNA. CRC Crit Rev Biochem 15: 1–24.

    Google Scholar 

  • Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochemistry 58: 351–375.

    Google Scholar 

  • Liu LF, Liu C-C and Alberts BM (1980) Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA moleculevia a reversible double-stranded break. Cell 19: 697–707.

    Google Scholar 

  • Liu LF and D'Arpa P (1992) Topoisomerase II-targeting antitumor drugs: mechanisms of cytotoxicity and resistance. Important Adv Oncol 1992: 79–89.

    Google Scholar 

  • Liu LF, Davis JL and Calendar R (1981) Novel topologically knotted DNA from bacteriophage P4 capsids: studies with DNA topoisomerases. Nucleic Acids Res 9: 3979–3989.

    Google Scholar 

  • Long BH, Musial ST and Brattain MG (1986) DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Cancer Res 46: 3809–3816.

    Google Scholar 

  • Lum BL, Gosland MP, Kaubisch S and Branimir BI (1993) Molecular targets in oncology: Implications of the multidrug resistance gene. Pharmacotherapy 13: 88–109.

    Google Scholar 

  • Marini JC, Miller KG and Englund PT (1980) Decatenation of kinetoplast DNA by topoisomerases. J Biol Chem 25: 4976–4979.

    Google Scholar 

  • Mattern MR, Mong S, Mong S-M, O'Leary Bartus J, Sarau HM, Clark MA, Foley JJ and Crooke ST (1990) Transient activation of topoisomerase I in leukotriene D4 signal transduction in human cells. Biochem J 265: 101–107.

    Google Scholar 

  • Mattern MR, Nambi P, O'Leary Bartus J, Mirabelli CK, Crooke ST and Johnson RK (1991) Regulation of topoisomerase I and II activities by cyclic nucleotide- and phospholipid-dependent protein kinases. Receptor 1: 181–190.

    Google Scholar 

  • McClean S and Hill BT (1992) An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugsin vitro. Biochim Biophys Acta 1114: 107–127.

    Google Scholar 

  • Mickisch GH, Pai LH, Gottesman MM, Pastan I and Schroeder FH (1993) MRK-16-Pseudomonas exotoxin conjugate reverses MDR in urogenital cancer and in MDR-transgenic mice. Proc Am Assoc Cancer Res 34: 317.

    Google Scholar 

  • Nambi P, Mattern M, O'Leary Bartus J, Aiyar N and Crooke ST (1989) Stimulation of intracellular topoisomerase I activity by vasopressin and thrombin. Differential regulation by pertussis toxin. Biochem J 262: 486–489.

    Google Scholar 

  • Nitiss JL, Liu YX and Hsiung Y (1993) A temperature-sensitive topoisomerase II allele confers temperature-dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 53: 89–93.

    Google Scholar 

  • Osheroff N (1986) Eukaryotic topoisomerase II. Characterization of enzyme turnover. J Biol Chem 261: 9944–9950.

    Google Scholar 

  • Per SR, Mattern MR, Mirabelli CK, Drake FH, Johnson RK and Crooke ST (1987) Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. Molec Pharmacol 32: 17–25.

    Google Scholar 

  • Pommier Y, Mattern MR, Schwartz RE, Zwelling LA and Kohn KW (1984) Changes in the deoxyribonucleic acid linking number due to treatment of mammalian cells with the intercalating agent 4′-(9-acridinylamino) methanesulfon-m-anisidide. Biochemistry 23: 2927–2932.

    Google Scholar 

  • Roberts D, Lee T, Parganas E, Wiggins L, Yalowich J and Ashmun R (1987) Expressions of resistance and crossresistance in teniposide resistant L1210 cells. Cancer Chemother Pharmacol 19: 123–130.

    Google Scholar 

  • Ross W, Rowe T, Glisson B and Liu L (1984) Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44: 5857–5860.

    Google Scholar 

  • Scala S, Dickstein B and Bates S (1993) Differential protein kinase modulation: Effect on P-glycoprotein (Pgp) transport. Proc Am Assoc Cancer Res 34: 317.

    Google Scholar 

  • Scotto KW and Prochaska H-P (1993) Collateral sensitivity of multidrug resistant cells to a new family of compounds. Proc Am Assoc Cancer Res 34: 314.

    Google Scholar 

  • Sela S, Hussain SR, Pearson J, Gottesman M, Longo D, Jacobson R and Rahman A (1993) Studies on modulation of multidrug resistance (MDR) in human colon HT-29 MDR-1 cancer cells. Proc Am Assoc Cancer Res 34: 324.

    Google Scholar 

  • Slater LM, Murray SL, Wetzel MW, Sweet P and Stupecky M (1986) Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance. Cancer Chemother Pharmacol 16: 50–54.

    Google Scholar 

  • Slater LM, Sweet P and Stupecky M (1993) Comparison of Cyclosporin A-,verapamil-, and cremophor EL-mediated enhancement of VP-16 cytotoxicity of L1210 and P388 leukemiasin vitro. Proc Am Assoc Cancer Res 34: 318.

    Google Scholar 

  • Soudon J, Berlion M, Lucas C, Haddad P, Bizzari JP and Calvo F (1993)In vitro time schedule modulation of multidrug resistance (MDR) with S 9788. Proc Am Assoc Cancer Res 34: 325.

    Google Scholar 

  • Spiridonidis CA, Chatterjee S, Petzold SJ and Berger NA (1989) Topoisomerase II-dependent and-independent mechanisms of etoposide resistance in Chinese hamster cell lines. Cancer Res 49: 644–650.

    Google Scholar 

  • Sullivan DM, Eskildsen LA, Groom KR, Webb CD, Latham MD, Martin AW, Wellhausen SR, Kroeger PE and Rowe TC (1993) Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line. Molec Pharmacol 43: 207–216.

    Google Scholar 

  • Sullivan DM, Glisson BS, Hodges PK, Smallwood-Kentro S and Ross WE (1986) Proliferation dependence of topoisomerase II-mediated drug action. Biochemistry 25: 2246–2256.

    Google Scholar 

  • Sullivan DM and Ross WE (1991) Resistance to inhibitors of DNA topoisomerases. Cancer Treat Res 57: 57–99.

    Google Scholar 

  • Takano H, Kohno K, Matsuo K, Matsuda T and Kuwano M (1992) DNA topoisomerase II-targeting antitumor agents and drug resistance. Anticancer Drugs 3: 323–330.

    Google Scholar 

  • Tan KB, Mattern MR, Eng W-k, McCabe FL and Johnson RK (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81: 1732–1735.

    Google Scholar 

  • Trask DK, DiDonato JA and Muller MT (1984) Rapid detection and isolation of covalent DNA-protein complexes: application to DNA topoisomerase I and II. Nuc Acids Res 11: 2779–2800.

    Google Scholar 

  • Utsugi T, Mattern MR, Mirabelli CK and Hanna N (1990) Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res 50: 2636–2640.

    Google Scholar 

  • Van der Zee AG, Hollema H, De Jong S, Boonstra H, Gouw A, Willemse PH, Zijlstra JG and De Vries EG (1991) P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51: 5915–5920.

    Google Scholar 

  • Volm M, Mattern J, Efferth T and Pommerenke EW (1992) Expression of several resistance mechanisms in untreated human kidney and lung carcinomas. Anticancer Res 12: 1063–1067.

    Google Scholar 

  • Wang JC (1985) DNA topoisomerases: enzymes that control DNA conformation. Annu Rev Biochem 54: 665–697.

    Google Scholar 

  • Webb CD, Latham MD, Lock RM and Sullivan DM (1991) Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51: 6543–6549.

    Google Scholar 

  • Woessner RD, Eng W-k, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB and Johnson RK (1993) Camptothecin hyperresistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncology Res 4: 481–488.

    Google Scholar 

  • Woessner RD, Mattern MR, Mirabelli CK, Johnson RK and Drake FH (1991) Proliferation- and cell cycle dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth and Differentiation 2: 209–214.

    Google Scholar 

  • Yang L, Rowe TC and Liu LF (1985) Identification of topoisomerase II as the intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Cancer Res 45: 5872–5876.

    Google Scholar 

  • Zwelling LA, Mayes J, Hinds M, Chan D, Altschuler E, Carroll B, Parker E, Deisseroth K, Radcliffe A, Seligman M, Li L and Farquhar D (1991) Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions. Biochemistry 30: 4048–4055.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomolecular Discovery, SmithKline Beecham Pharmaceuticals, P.O. Box 1539, 19406, King of Prussia, PA, USA

    Glenn A. Hofmann & Michael R. Mattern

Authors
  1. Glenn A. Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael R. Mattern
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hofmann, G.A., Mattern, M.R. Topoisomerase II in multiple drug resistance. Cytotechnology 12, 137–154 (1993). https://doi.org/10.1007/BF00744662

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00744662

Key words

Search

Navigation